
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is well-positioned for long-term growth with a strong technology portfolio, expanding clinical and economic case for CGM adoption in the T2NIT population, and an anticipated CMS coverage expansion. The company's recent CONNECT and ADA data demonstrate the benefits and synergies of CGM in combination with GLP-1 and SGLT-2 therapies. Additionally, strong margins and rising NRx figures indicate positive growth potential in both the US and international markets, with a goal of driving CGM adoption across all aspects of diabetes care.
Bears say
DexCom is facing several challenges, including pricing pressures from payors and potential delays in commercializing new products. Additionally, the company's revenue growth for 2026 was largely due to fuel-related impacts, rather than organic growth. Furthermore, DexCom's revenue for the first quarter of 2026 was mixed, with US sales missing expectations and the company relying on international sales for growth. These factors contribute to our negative outlook on the company's stock.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares